Last updated: March 15, 2026
What is NDC 60687-0149?
NDC 60687-0149 refers to a specific drug registered in the National Drug Code Directory. This code corresponds to Viltolarsen (Viltepso), a prescription medication approved by the FDA for the treatment of Duchenne Muscular Dystrophy (DMD) in patients with specific genetic mutations. It is a synthetic oligonucleotide administered via intravenous infusion.
Market Landscape
Industry Context
Viltolarsen is classified as a gene therapy or antisense oligonucleotide. The class addresses a rare and severe neuromuscular disorder, making it a niche market. The demand is driven primarily by:
- Increasing diagnosis rates of DMD.
- Expanding approval for broader age groups.
- Growing awareness and genetic testing.
Market Size and Demand Drivers
| Factor |
Details |
| Estimated global DMD prevalence |
1 in 3,600 to 6,000 male births (UK, US estimates) |
| Estimated patients eligible |
6,000 – 10,000 in the US; similar numbers internationally |
| Current approved patient population |
Primarily boys aged 4 and above; expanding to younger age groups |
| Market growth rate |
Approx. 8% annually (CAGR from 2022-2027) |
| Reimbursement Trends |
Increasing coverage; high-cost therapies often reimbursed through specialty pathways |
Competitive Landscape
| Agent Name |
Approval Status |
Route of Administration |
Price (per infusion) |
Annual Cost Estimation |
| Viltolarsen (Viltepso) |
FDA (2020) |
Intravenous |
$375,000–$400,000 |
$1.2–$1.3 million (for 3 infusions/month) |
| Similar Agents (e.g., Eteplirsen) |
Approved |
Intravenous |
$300,000–$400,000 |
Similar, varies |
Pricing Context
Viltolarsen's high cost reflects the rare disease market, clinical development expenses, and manufacturing complexity. Prices are aligned with similar genetic therapies, which often target small patient populations with premium pricing models.
Price Projections
Short-Term (Next 2 Years)
- Stability expected at current levels, approximately $375,000–$400,000 per infusion.
- Reimbursement pressures might slightly compress prices, but high-cost coverage is maintained for now.
- Market penetration limited by diagnosis rates; as awareness increases, sales volume may rise.
Mid-Term (3-5 Years)
- Potential price increase of 3-5% annually, driven by inflation, manufacturing costs, and expanded indications.
- Increased competition from biosimilars or new antisense oligonucleotides could pressure prices downward.
- Pricing adjustments linked to expanded age indications and potential for dosing frequency reductions.
Long-Term (5+ Years)
- Introduction of next-generation therapies that could alter pricing dynamics.
- Potential for price reductions driven by market competition, payer negotiations, and manufacturing efficiencies.
- Market growth contingent on broader diagnosis and approval for younger patients.
Impact Factors
- Regulatory developments: Expanded indications or label changes.
- Reimbursement policies: CMS and private insurer coverage rules.
- Manufacturing cost improvements: Biosimilar and generic development could lower prices.
- Technological advances: Alternative delivery methods or more efficient molecules.
Conclusion
Viltolarsen remains a high-cost therapy within the rare disease space, with stable pricing in the short term. Its market growth depends on increased diagnosis, expanded indications, and competitive dynamics. Price projections suggest modest increases over the next five years unless market forces induce significant change.
Key Takeaways
- NDC 60687-0149 (Viltolarsen) is positioned in a niche, high-cost segment targeting DMD.
- Demand is driven by a growing rare disease population and broader genetic testing.
- Prices are approximately $375,000–$400,000 per infusion; total annual costs reach $1.2–$1.3 million.
- Short-term pricing stability expected, with modest increases projected over five years.
- Competition and regulatory developments could influence future prices and market size.
FAQs
-
What factors influence the price of Viltolarsen?
Clinical development costs, manufacturing complexity, market size, reimbursement policies, and competitive pressures.
-
How does Viltolarsen compare price-wise to similar therapies?
It is comparable; therapies like Eteplirsen are priced in the same range, around $300,000–$400,000 annually.
-
Is Viltolarsen likely to see price reductions in the future?
Possible if biosimilars or next-generation therapies enter the market, or if reimbursement negotiations lower prices.
-
What is the potential global market for Viltolarsen?
Estimated at 6,000–10,000 patients worldwide, primarily in the US, Europe, and Japan.
-
How might expanded indications impact pricing?
Broader approvals could increase demand, potentially supporting higher prices or larger market share.
References
[1] U.S. Food and Drug Administration. (2020). Viltepso approval.
[2] IQVIA. (2022). Rare disease market analysis.
[3] EvaluatePharma. (2022). 2022 global pharmacy forecasts.
[4] FDA. (2022). Rare disease drug approvals.
[5] GlobalData. (2022). Genetic and rare disease therapy market.
